Bengaluru: Celldex Therapeutics said on Thursday it would stop developing its experimental drug for eczema after the treatment failed to meet the main and key secondary goals of a mid-stage study.
The study enrolled 131 patients with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition commonly known as eczema.
The drug, barzolvolimab, did not significantly reduce itching after 16 weeks and showed no meaningful improvement over placebo on other key measures.
The drug reduced mast cells, immune cells involved in allergic and inflammatory reactions, but the results suggest they are not the main driver of atopic dermatitis, the company said.
Celldex said the limited improvements fell short of its threshold for further development, with no added benefit after 32 weeks
The treatment was well tolerated, with a safety profile consistent with earlier studies.
Celldex will continue late-stage studies of barzolvolimab in three hive-related skin conditions: chronic spontaneous urticaria, cold urticaria and symptomatic dermographism.
The company plans to seek US approval for the drug in chronic spontaneous urticaria in 2027 and announce additional indications by year-end.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.